2'-(benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid | 332378-33-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2'-(benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid
• 英文别名: 2-[2-(phenylmethoxycarbonylaminomethyl)phenyl]benzoic acid
• CAS: 332378-33-3
• 化学式: C₂₂H₁₉NO₄
• 分子量: 361.397
• InChiKey: MCJOUORSTIRIDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  异戊醇 、 2'-(benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 在 1-羟基苯并三唑 、 N,N'-二异丙基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以37%的产率得到3-Methylbutyl 2-[2-(phenylmethoxycarbonylaminomethyl)phenyl]benzoate
  参考文献：
  名称：

  Identification, Synthesis, and Activity of Novel Blockers of the Voltage-Gated Potassium Channel Kv1.5

  摘要：

  The voltage-gated potassium channel Kv1.5 is regarded as a promising target for the development of new atrial selective drugs with fewer side effects. In the present study the discovery of ortho,ortho-disubstituted bisaryl compounds as blockers of the Kv1.5 channel is presented. Several compounds of this new class were synthesized and screened for their ability to block Kv1.5 channels expressed in Xenopus oocytes. The observed structure-activity relationship (SAR) is described by a pharmacophore model that consists of three hydrophobic centers in a triangular arrangement. The hydrophobic centers are matched by a phenyl or pyridyl ring of the bisaryl core and both ends of the side chains. The most potent compounds (e.g., 17c and 17o) inhibited the Kv1.5 channel with sub-micromolar half-blocking concentrations and displayed 3-fold selectivity over Kv1.3 and no significant effect on the HERG channel and sodium currents. In addition, compounds 17c and 17m have already shown antiarrhythmic effects in a pig model.

  DOI：

  10.1021/jm0210461
• 作为产物：
  描述：

  2'-(phthalimidomethyl)biphenyl-2-carboxylic acid 在 碳酸氢钠 、 一水合肼 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 5.5h， 生成 2'-(benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid
  参考文献：
  名称：

  Identification, Synthesis, and Activity of Novel Blockers of the Voltage-Gated Potassium Channel Kv1.5

  摘要：

  The voltage-gated potassium channel Kv1.5 is regarded as a promising target for the development of new atrial selective drugs with fewer side effects. In the present study the discovery of ortho,ortho-disubstituted bisaryl compounds as blockers of the Kv1.5 channel is presented. Several compounds of this new class were synthesized and screened for their ability to block Kv1.5 channels expressed in Xenopus oocytes. The observed structure-activity relationship (SAR) is described by a pharmacophore model that consists of three hydrophobic centers in a triangular arrangement. The hydrophobic centers are matched by a phenyl or pyridyl ring of the bisaryl core and both ends of the side chains. The most potent compounds (e.g., 17c and 17o) inhibited the Kv1.5 channel with sub-micromolar half-blocking concentrations and displayed 3-fold selectivity over Kv1.3 and no significant effect on the HERG channel and sodium currents. In addition, compounds 17c and 17m have already shown antiarrhythmic effects in a pig model.

  DOI：

  10.1021/jm0210461

文献信息

• 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20030171351A1

  公开（公告）日：2003-09-11

  Compounds of the formula I, 1 in which R(1), R(2), R(3), R(4), R(5), R(6), R(7), R(8), R(30) and R(31) have the meanings indicated in the claims, are very particularly suitable as novel and antiarrythmic active compounds, in particular for the treatment and prophylaxis of atrial arrythmias, e.g. atrial fibrillation (AF), or atrial flutter.

  化学式为I,1的化合物，其中R(1), R(2), R(3), R(4), R(5), R(6), R(7), R(8), R(30)和R(31)的含义如权利要求中所示，非常适用作为新型和抗心律失常活性化合物，特别是用于治疗和预防心房心律失常，例如心房颤动(AF)或心房扑动。
• 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040102513A1

  公开（公告）日：2004-05-27

  Compounds of the formula I, 1 in which R(1), R(2), R(3), R(4), R(5), R(6), R(7), R(8), R(30) and R(31) have the meanings indicated in the claims, are very particularly suitable as novel and antiarrythmic active compounds, in particular for the treatment and prophylaxis of atrial arrythmias, e.g. atrial fibrillation (AF), or atrial flutter.

  公式为I,1的化合物，其中R(1)、R(2)、R(3)、R(4)、R(5)、R(6)、R(7)、R(8)、R(30)和R(31)的含义如权利要求所示，非常适用于作为新型和抗心律失常活性化合物，特别适用于治疗和预防心房心律失常，例如心房颤动（AF）或心房扑动。
• 2′-substituted 1,1′-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US06686395B2

  公开（公告）日：2004-02-03

  Compounds of the formula I, in which R(1), R(2), R(3), R(4), R(5), R(6), R(7), R(8), R(30) and R(31) have the meanings indicated in the claims, are very particularly suitable as novel and antiarrythmic active compounds, in particular for the treatment and prophylaxis of atrial arrythmias, e.g. atrial fibrillation (AF), or atrial flutter.

  式I的化合物，其中R(1)，R(2)，R(3)，R(4)，R(5)，R(6)，R(7)，R(8)，R(30)和R(31)具有所述要求中指定的含义，非常适用作为新型的抗心律失常活性化合物，特别是用于治疗和预防心房心律失常，例如心房颤动(AF)或心房扑动。
• 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US06531495B1

  公开（公告）日：2003-03-11

  Compounds of the formula I, in which R(1), R(2), R(3), R(4), R(5), R(6), R(7), R(8), R(30) and R(31) have the meanings indicated in the claims, are very particularly suitable as novel and antiarrythmic active compounds, in particular for the treatment and prophylaxis of atrial arrythmias, e.g. atrial fibrillation (AF), or atrial flutter.

  公式I的化合物，其中R（1）、R（2）、R（3）、R（4）、R（5）、R（6）、R（7）、R（8）、R（30）和R（31）具有声明中所指示的含义，非常适用于作为新型和抗心律失常活性化合物，特别用于治疗和预防心房心律失常，例如心房颤动（AF）或心房扑动。
• 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：US07514582B2

  公开（公告）日：2009-04-07

  Compounds of the formula I, in which R(1), R(2), R(3), R(4), R(5), R(6), R(7), R(8), R(30) and R(31) have the meanings indicated in the claims, are very particularly suitable as novel and antiarrythmic active compounds, in particular for the treatment and prophylaxis of atrial arrythmias, e.g. atrial fibrillation (AF), or atrial flutter.

  公式I中的化合物，其中R（1），R（2），R（3），R（4），R（5），R（6），R（7），R（8），R（30）和R（31）具有索权所示的含义，非常适用作为新的和抗心律失常活性化合物，特别是用于治疗和预防房颤（AF）或房扑动。